Forte Biosciences, Inc.

General ticker "FBRX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $131.8M (TTM average)

Forte Biosciences, Inc. follows the US Stock Market performance with the rate: 43.9%.

Estimated limits based on current volatility of 4.5%: low 29.90$, high 32.73$

Factors to consider:

  • Total employees count: 67 as of 2017
  • Current price 74.2% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [9.23$, 29.61$]
  • 2025-12-31 to 2026-12-31 estimated range: [4.86$, 17.38$]

Financial Metrics affecting the FBRX estimates:

  • Negative: with PPE of -1.1 at the end of fiscal year the price was high
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -51.84 <= 0.01
  • Negative: negative Net income
  • Positive: Interest expense per share per price, % of 0 <= 0.01
  • Positive: Inventory ratio change, % of 0 <= 0

Similar symbols

Short-term FBRX quotes

Long-term FBRX plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $13.90MM $32.49MM $36.60MM
Operating Income $-13.90MM $-32.49MM $-36.60MM
Non-Operating Income $0.02MM $1.01MM $1.12MM
R&D Expense $5.59MM $21.86MM $21.19MM
Income(Loss) $-13.88MM $-31.48MM $-35.48MM
Profit(Loss)* $-13.86MM $-31.48MM $-35.48MM
Stockholders Equity $38.82MM $35.31MM $52.48MM
Assets $42.00MM $38.98MM $61.56MM
Operating Cash Flow $-8.19MM $-28.71MM $-30.75MM
Capital expenditure $0.00MM $0.09MM $0.04MM
Investing Cash Flow $0.00MM $0.05MM $-35.99MM
Financing Cash Flow $7.24MM $24.68MM $51.86MM
Earnings Per Share** $-19.94 $-24.92 $-12.17

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.